Featured News February 24, 2026Ophirex to Supply Marimastat Drug Substance to Liverpool School of Tropical Medicine for Novel Snakebite Treatment ResearchOphirex, Inc., a Public Benefit Corporation developing novel treatments for snakebite envenomation, today announced it has entered into an agreement to produce marimastat, an inhibitor of snake venom metalloproteinases, for Liverpool School of Tropical Medicine (LSTM). The drug substance will be used in the LSTM’s Centre for Snakebite Research & Interventions’ (CSRI) TOCSINS clinical trial: a phase 2 platform trial of novel oral snakebite treatments funded by a £4.2 million grant from Coefficient Giving.Press Releases Featured Media Load More
February 24, 2026Ophirex to Supply Marimastat Drug Substance to Liverpool School of Tropical Medicine for Novel Snakebite Treatment ResearchOphirex, Inc., a Public Benefit Corporation developing novel treatments for snakebite envenomation, today announced it has entered into an agreement to produce marimastat, an inhibitor of snake venom metalloproteinases, for Liverpool School of Tropical Medicine (LSTM). The drug substance will be used in the LSTM’s Centre for Snakebite Research & Interventions’ (CSRI) TOCSINS clinical trial: a phase 2 platform trial of novel oral snakebite treatments funded by a £4.2 million grant from Coefficient Giving.
